'Linkage' pharmaceutical evergreening in Canada and Australia

Australia and New Zealand Health Policy

Volumn 4, Issue 1, 2007, Pages

  Faunce, Thomas A ^a   Lexchin, Joel ^b  

^a The Australian National University   (Australia)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG; TORCETRAPIB;

ARTICLE; AUSTRALIA; CANADA; COMMERCIAL PHENOMENA; COMPETITION; COURT; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PACKAGING; DRUG QUALITY; DRUG SAFETY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; KOREA; LAW; PATENT; PRIORITY JOURNAL; PROFIT; THREAT; UNITED STATES;

EID: 34347250879     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-4-8     Document Type: Article

References (62)

1. Waxman-Hatch Act (35 USC §156) Mossinghoff G Overview of the Hatch-Waxman Act and Its Impact on the Drug Development Process Food and Drug Law Journal 1999 54 187-193
2. Glasgow L Stretching the limits of intellectual property rights: Has the pharmaceutical industry gone too far? IDEA -Journal of Law and Technology 2002 41 2001-227
3. Generic Drug Entry Prior to Patent Expiration: An FTC Study Federal Trade Commission 2002
4. Biles B Hersch Nicholas L Cooper BS Adrion E Guterman S The cost of privatization: Extra payments to Medicare Advantage plans-updated and revised The Commonwealth Fund 2006, November 1-14
5. The electronic copy of the Patent Register http://www.patentregister.ca/ accessed 27 May, 2007
6. Health Canada Therapeutic Products Directorate Statistical Report Patented Medicines (Notice of Compliance) Regulations by the Office of Patented Medicines and Liaison 2002 http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/docs/patmedbrev/patmrep_mbrevrap_2002_e.html accessed 8 October, 2006
7. Canadian Generic Pharmaceutical Association The patented medicines (notice of compliance) regulations http://www.cdma-acfpp.org/en/issues/ noc_regulations.html accessed 15 January, 2006.
8. Rx&D S-17: A necessary first step to bring Canada's patent act to internationally competitive standards. A brief to the House of Commons Standing Committee on Industry, Science and Technology Ottawa May 29, 2001
9. Rx&D S-17: A necessary first step to bring Canada's patent act to internationally competitive standards. A brief to the House of Commons Standing Committee on Industry, Science and Technology Ottawa May 29, 2001
10. Canadian Generic Pharmaceutical Association The patented medicines (notice of compliance) regulations http://www.cdma-acfpp.org/en/issues/ noc_regulations.html accessed 15 January, 2006
11. Office of Patented Medicines and Liaison Therapeutic Products Directorate statistical report 2004: Patented medicines (notice of compliance) regulations Health Canada 2005
12. Office of Patented Medicines and Liaison Therapeutic Products Directorate statistical report 2004: Patented medicines (notice of compliance) regulations Health Canada 2005
13. Rx&D S-17: A necessary first step to bring Canada's patent act to internationally competitive standards. A brief to the House of Commons Standing Committee on Industry, Science and Technology Ottawa May 29, 2001
14. Government of Canada. Canada Gazette Part II Regulations amending the patented medicines (notice of compliance) regulations 2006 140 21 1503-1525
15. Canadian Generic Pharmaceutical Association. Supreme Court decision proves Fed's gift to big pharma unnecessary http://www.canadiangenerics.ca/en/news/nov_03_06.shtml accessed 10 December 2006
16. Avorn J Torcetrapib and Atorvastatin - Should Marketing Drive the Research Agenda? New England Journal of Medicine 2005 352 2573-2576 10.1056/NEJMp058075
17. US Food and Drug Administration Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety http://www.fda.gov/bbs/topics/NEWS/ 2006/NEW01514.html accessed 7 May 2007
18. Burdon M Sloper K The Art of Using Secondary Patents to Improve Protection International Journal of Medical Marketing 2003 3 226-229 10.1057/palgrave.jmm.5040125
19. Aktiebolaget Hassle v Alphapharm Pty Ltd, 212 CLR 411 2002
20. Aktiebolaget Hassle v Alphapharm Pty Ltd, 212 CLR 411, para 101 2002
21. Arrow Pharmaceuticals Limited v Merck & Co., Inc, FCA 1282; 63 IPR 85 2004
22. Arrow Pharmaceuticals Limited v Merck & Co., Inc, FCA 1282 at para 80 2004
23. Arrow Pharmaceuticals Limited v Merck & Co., Inc, FCA 1282 at para 1 2004
24. United States Federal Trade Commission Generic Drug Entry Prior to Patent Expiry: An FTC Study. 2002; Office of Patented Medicines and Liaison, Health Canada: Therapeutic Products Directorate. Statistical Report 2003: Patented Medicines (Notice of Compliance) Regulations 21 June 2004
25. Commonwealth of Australia Senate Inquiry into the AUSFTA http://www.aph.gov.au/Senate/committee/freetrade_ctte/hearings/index.htm 21 June 2004, accessed 29 September, 2006
26. Faunce T Doran E Henry D Drahos P Searles P Pekarsky B Neville W Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy Globalisation and Health 2005 1 1-15 10.1186/1744-8603-1-1
27. For a good discussion on evergreening techniques and the Hatch-Waxman law see National Institute for Health Care Management Changing Patterns of Pharmaceutical Innovation Research Report 2002
28. Senate Select Committee on the Free Trade Agreement between Australia and the US http://www.aph.gov.au/Senate/committee/freetrade_ctte/report/ final/index.htm accessed 8 October, 2006
29. Deady S Special Negotiator Office of Trade Negotiations Dept. Foreign Affairs and Trade. Senate Select Committee on the Free Trade Agreement between Australia and the United States of America Official Committee Hansard 12-16 http://www.aph.gov.au/Senate/committee/freetrade_ctte/ hearings/index.htm Monday 21 June 2004, accessed 1 Feb 2007
30. Deady S Special Negotiator, Office of Trade Negotiations, Department of Foreign Affairs and Trade, Commonwealth of Australia Evidence to Senate Select Committee on the FTA Between Australia and the USA, Parliament of Australia, Canberra Monday 21 June 2004: 31, 33, 48.
31. Letter From Robert Zoellick, USTR, to Mark Vaile, Australian Minister for Trade http://www.ustr.gov/assets/Trade_Agreements/Bilateral/ Australia_FTA/Implementation/asset_upload_file393_6951.pdf 17 November 2004, accessed 18 October, 2006
32. Office of the US Trade Representative Proposed text: US-Korea Free Trade Agreement http://www.ustr.gov/Trade_Agreements/Bilateral/ Republic_of_Korea_FTA/Draft_Text/Section_Index.html accessed 29 May 2007
33. Anonymous "NPS raises 'evergreeening bogey" Pharma in Focus 22 January 2007
34. PhRMA PhRMA Special 301 submission: Canada http://www.phrma.org/ international/resources/03.03.2003.349.cfm accessed 24 May, 2007
35. Office of the United States Trade Representative 2006 National Trade Estimate Report on Foreign Trade Barriers http://www.ustr.gov/ Document_Library/Reports_Publications/2006/2006_NTE_Report/ Section_Index.html?ht accessed 20 June, 2006
36. Government of Canada Canada Gazette Part II. Regulations amending the patented medicines (notice of compliance) regulations
37. Letter from Robert Zoellick to Mark Vaile (Item 6 (Pharmaceutical Patents)) Department of Foreign Affairs and Trade http://www.dfat.gov.au/ trade/negotiations/us_fta/final-text/letters/ip_zoellick_vaile.pdf 18 May 2004, accessed July, 2005
38. US still watchful on FTA Pharma in Focus http://www.pharmainfocus.com.au/ news.asp?newsid=517 22 November 2004, accessed 12 September, 2005
39. Hansen PI Judicialization and Globalization in the North American Free Trade Agreement Texas International Law Journal 2003 38 489-498 at 491
40. The North American Free Trade Agreement, opened for signature: 17 December 31 I.L.M. 289 (ch 1-9) 32 I.L.M. 605 (ch 10-22) (entered into force 1 January 1994) (hereafter NAFTA) Chapter 20; Understanding on Rules and Procedures Governing the Settlement of Disputes, opened for signature 15 April 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 2, Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations 353, 33 I.L.M. 1125, 1226 (1994) 1992 hereinafter WTO DSU
41. Article 8.3, WTO DSU
42. Palmeter D Mavroidis PC Dispute Settlement in the World Trade Organization: Practice and Procedure Cambridge: Cambridge University Press 2 2004 105
43. Hansen PI Judicialization and Globalization in the North American Free Trade Agreement Texas International Law Journal 2003 38 489-498 at 491
44. Agricultural Products Tariffication (US v Canada) and Safeguards on Brooms (Mexico v US) In Gantz DA Dispute Settlement Under the NAFTA and the WTO: Choice of Forum Opportunities and Risks for the NAFTA Parties American University International Law Review 1999 14 1025 at 1063, 1067
45. Gantz DA Dispute Settlement under the NAFTA and the WTO: Choice of Forum Opportunities and Risks for NAFTA Parties American University International Law Review 1999 14 1025-1043 at 1041
46. Deputy Prime Minister and Minister for Trade, Mark Vaile Second Reading Speech on the Introduction of the US Free Trade Agreement Implementation Bill Canberra 2004 http://www.trademinister.gov.au/speeches/2004/ 040623_2nd_reading_usfta.html accessed 12 October, 2006
47. US Trade Representative US-Australia Free Trade Agreement-Questions and Answers about Pharmaceuticals Washington DC 2004 http://www.ustr.gov/ Document_Library/Fact_Sheets/2004/
48. Deady S Special Negotiator, Office of Trade Negotiations, Department of Foreign Affairs and Trade Senate Select Committee on the Free Trade Agreement between Australia and the United States of America 2004
49. International pharma crits FTA Pharma in Focus http://www.pharmainfocus.com.au/news.asp?newsid=469 25 October 2004, accessed 12 September, 2005
50. See Canada - Patent Protection of Pharmaceutical Products WTO Doc WT/ DS114/R 2000 5.9 Report of the Panel
51. Japan - Measures Affecting Consumer Photographic Film and Paper WTO Doc WT/DS44/R (1998) (Report of the Panel); affirmed by European Communities -Measures Affecting Asbestos and Asbestos-Containing Products WTO Doc WT/ DB153/AB/R, AB-2000-11 2001 Report of the Appellate Body
52. European Communities - Measures Affecting Asbestos and Asbestos-Containing Products WTO Doc WT/DS135/R 2000 8.276 Report of the Panel
53. Korea - Measures Affecting Government Procurement WTO Doc WT/DS163/R 2000 7.100-7.102 Report of the Panel
54. Korea - Measures Affecting Government Procurement WTO Doc WT/DS163/R 2000 7.122 Report of the Panel
55. US Trade Representative US-Australia Free Trade Agreement-Questions and Answers about Pharmaceuticals Washington DC 2004 http://www.ustr.gov/ Document_Library/Fact_Sheets/2004/
56. Deady S Special Negotiator, Office of Trade Negotiations, Department of Foreign Affairs and Trade Senate Select Committee on the Free Trade Agreement between Australia and the United States of America 2004
57. International pharma crits FTA Pharma in Focus http://www.pharmainfocus.com.au/news.asp?newsid=469 25 October 2004, accessed 12 September, 2005
58. See Canada - Patent Protection of Pharmaceutical Products WTO Doc WT/ DS114/R 2000 5.9 Report of the Panel
59. Japan - Measures Affecting Consumer Photographic Film and Paper WTO Doc WT/DS44/R (1998) (Report of the Panel); affirmed by European Communities -Measures Affecting Asbestos and Asbestos-Containing Products WTO Doc WT/ DB153/AB/R, AB-2000-11 2001 Report of the Appellate Body
60. European Communities - Measures Affecting Asbestos and Asbestos-Containing Products WTO Doc WT/DS135/R 2000 8.276 Report of the Panel
61. Korea - Measures Affecting Government Procurement WTO Doc WT/DS163/R 2000 7.100-7.102 Report of the Panel
62. Korea - Measures Affecting Government Procurement WTO Doc WT/DS163/R 2000 7.122 Report of the Panel